Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein

Journal of Immunology

Volumn 181, Issue 2, 2008, Pages 931-939

  Yolcu, Esma S ^a,b   Gu, Xiao ^a   Lacelle, Chantale ^a   Zhao, Hong ^a   Bandura Morgan, Laura ^a   Askenasy, Nadir ^c   Shirwan, Haval ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; TRANSCRIPTION FACTOR FOXP3; GAMMA INTERFERON; HYBRID PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BIOENGINEERING; CD4+ CD25+ T LYMPHOCYTE; CELL SORTER; CELL SURFACE; CONTROLLED STUDY; DONOR; GRAFT RECIPIENT; HEART TRANSPLANTATION; IMMUNOMODULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; SPLEEN CELL; ALLOTRANSPLANTATION; ANIMAL; AUGUST COPENHAGEN IRISH RAT; CELL PROLIFERATION; CYTOLOGY; FISCHER 344 RAT; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; METABOLISM; SPLEEN; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE; WISTAR FURTH RAT;

ADOPTIVE TRANSFER; ANIMALS; CELL PROLIFERATION; FAS LIGAND PROTEIN; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; INTERFERON TYPE II; MALE; RATS; RATS, INBRED ACI; RATS, INBRED F344; RATS, INBRED WF; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 49049110769     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.2.931     Document Type: Article

References (56)

1. Salama, A. D., K. L. Womer, and M. H. Sayegh. 2007. Clinical transplantation tolerance: many rivers to cross. J. Immunol. 178: 5419-5423. (Pubitemid 46674334)
2. Newell, K. A., and C. P. Larsen. 2007. Transplantation tolerance. Semin. Nephrol. 27: 487-497.
3. Merrill, J. P., J. E. Murray, J. H. Harrision, and W. R. Guild. 1956. Successful homotransplantation of the human kidney between identical twins. JAMA 160: 277-282.
4. Shirwan, H. 2006. Allograft tolerance: is it a journey towards achieving the impossible? Curr. Opin. Org. Transpl. 11: 351-353. (Pubitemid 44114530)
5. Horn, P. A., C. Figueiredo, and H. P. Kiem. 2007. Gene therapy in the transplantation of allogeneic organs and stem cells. Curr. Gene Ther. 7: 458-468. (Pubitemid 350268181)
6. Anderson, W. F. 2000. Gene therapy: the best of times, the worst of times. Science 288: 627-629.
7. Catron, D. M., A. A. Itano, K. A. Pape, D. L. Mueller, and M. K. Jenkins. 2004. Visualizing the first 50 hr of the primary immune response to a soluble antigen. Immunity 21: 341-347.
8. Yolcu, E. S., N. Askenasy, N. P. Singh, S. E. Cherradi, and H. Shirwan. 2002. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17: 795-808.
9. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178. (Pubitemid 24006113)
10. Refaeli, Y., L. Van Parijs, C. A. London, J. Tschopp, and A. K. Abbas. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 615-623. (Pubitemid 28264752)
11. Askenasy, N., E. S. Yolcu, I. Yaniv, and H. Shirwan. 2004. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 105: 1396-1404. (Pubitemid 40223653)
12. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94: 3943-3947. (Pubitemid 27180478)
13. Kang, S. M., D. B. Schneider, Z. Lin, D. Hanahan, D. A. Dichek, P. G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3: 738-743.
14. Lau, H. T., and C. J. Stoeckert. 1997. FasL: too much of a good thing? Transplanted grafts of pancreatic islet cells engineered to express Fas ligand are destroyed not protected by the immune system. Nat. Med. 3: 727-728.
15. Lau, H. T., M. Yu, A. Fontana, and C. J. Stoeckert, Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273: 109-112.
16. Matsue, H., K. Matsue, M. Walters, K. Okumura, H. Yagita, and A. Takashima. 1999. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells. Nat. Med. 5: 930-937.
17. Min, W. P., R. Gorczynski, X. Y. Huang, M. Kushida, P. Kim, M. Obataki, J. Lei, R. M. Suri, and M. S. Cattral. 2000. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. 164: 161-167.
18. Swenson, K. M., B. Ke, T. Wang, J. S. Markowitz, M. A. Maggard, G. S. Spear, D. K. Imagawa, J. A. Goss, R. W. Busuttil, and P. Seu. 1998. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 65: 155-160. (Pubitemid 28099204)
19. Takeuchi, T., T. Ueki, H. Nishimatsu, T. Kajiwara, T. Ishida, K. Jishage, O. Ueda, H. Suzuki, B. Li, N. Moriyama, and T. Kitamura. 1999. Accelerated rejection of Fas ligand-expressing heart grafts. J. Immunol. 162: 518-522. (Pubitemid 29018962)
20. Zhang, H., Y. Yang, J. L. Horton, E. B. Samoilova, T. A. Judge, L. A. Turka, J. M. Wilson, and Y. Chen. 1997. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J. Clin. Invest. 100: 1951-1957. (Pubitemid 27459348)
21. Suda, T., H. Hashimoto, M. Tanaka, T. Ochi, and S. Nagata. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186: 2045-2050. (Pubitemid 28013689)
22. Tanaka, M., T. Itai, M. Adachi, and S. Nagata. 1998. Downregulation of Fas ligand by shedding. Nat. Med. 4: 31-36.
23. Ottonello, L., G. Tortolina, M. Amelotti, and F. Dallegri. 1999. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 162: 3601-3606. (Pubitemid 29313614)
24. Seino, K., K. Iwabuchi, N. Kayagaki, R. Miyata, I. Nagaoka, A. Matsuzawa, K. Fukao, H. Yagita, and K. Okumura. 1998. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161: 4484-4488. (Pubitemid 28492016)
25. Askenasy, N., E. S. Yolcu, Z. Wang, and H. Shirwan. 2003. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 107: 41-47. (Pubitemid 36378492)
26. Shirwan, H., L. Barwari, I. Fuss, L. Makowka, and D. V. Cramer. 1995. Structure and repertoire usage of rat TCR α-chain genes in T cells infiltrating heart allografts. J. Immunol. 154: 1964-1972.
27. Koksoy, S., T. P. Kakoulidis, and H. Shirwan. 2004. Chronic heart allograft rejection in rats demonstrates a dynamic interplay between IFN-γ and IL-10 producing T cells. Transpl. Immunol. 13: 201-209. (Pubitemid 39285977)
28. Shirwan, H., A. Mhoyan, E. S. Yolcu, X. Que, and S. Ibrahim. 2003. Chronic cardiac allograft rejection in a rat model disparate for one single class I MHC molecule is associated with indirect recognition by CD4+ T cells. Transpl. Immunol. 11: 179-185. (Pubitemid 36740811)
29. Hosenpud, J. D., J. P. Everett, T. E. Morris, K. A. Mauck, G. D. Shipley, and C. R. Wagner. 1995. Cardiac allograft vasculopathy: association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium. Circulation 92: 205-211.
30. + T cells. Int. Immunol. 7: 1331-1337.
31. Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, and D. Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335: 271-274. (Pubitemid 18224875)
32. Suchin, E. J., P. B. Langmuir, E. Palmer, M. H. Sayegh, A. D. Wells, and L. A. Turka. 2001. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166: 973-981.
33. + T cell-mediated rejection of pancreatic islet allografts. J. Immunol. 165: 247-255.
34. Miura, M., K. Morita, H. Kobayashi, T. A. Hamilton, M. D. Burdick, R. M. Strieter, and R. L. Fairchild. 2001. Monokine induced by IFN-γ is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J. Immunol. 167: 3494-3504. (Pubitemid 32852596)
35. Wood, K. J., and S. Sakaguchi. 2003. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3: 199-210.
36. Arai, H., S. Y. Chan, D. K. Bishop, and G. J. Nabel. 1997. Inhibition of the alloantibody response by CD95 ligand. Nat. Med. 3: 843-848. (Pubitemid 27353442)
37. Matsue, H., K. Matsue, M. Kusuhara, T. Kumamoto, K. Okumura, H. Yagita, and A. Takashima. 2001. Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells. Blood 98: 3465-3472.
38. Tourneur, L., B. Malassagne, F. Batteux, M. Fabre, S. Mistou, E. Lallemand, P. Lores, and G. Chiocchia. 2001. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts. J. Immunol. 167: 1338-1346. (Pubitemid 32703130)
39. Whartenby, K. A., E. E. Straley, H. Kim, F. Racke, V. Tanavde, K. S. Gorski, L. Cheng, D. M. Pardoll, and C. I. Civin. 2002. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 100: 3147-3154.
40. Zhang, H. G., X. Su, D. Liu, W. Liu, P. Yang, Z. Wang, C. K. Edwards, H. Bluethmann, J. D. Mountz, and T. Zhou. 1999. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J. Immunol. 162: 1423-1430. (Pubitemid 29307014)
41. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291: 2413-2417. (Pubitemid 32231804)
42. +FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-β dependent but does not confer a regulatory phenotype. Blood 110: 2983-2990.
43. Zhang, Z. X., L. Yang, K. J. Young, B. DuTemple, and L. Zhang. 2000. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat. Med. 6: 782-789.
44. + T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transpl. Immunol. 13: 239-247.
45. Guillonneau, C., M. Hill, F. X. Hubert, E. Chiffoleau, C. Herve, X. L. Li, M. Heslan, C. Usal, L. Tesson, S. Menoret, et al. 2007. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-γ, and indoleamine 2,3-dioxygenase. J. Clin. Invest. 117: 1096-1106. (Pubitemid 46556766)
46. Minagawa, R., S. Okano, Y. Tomita, K. Kishihara, H. Yamada, K. Nomoto, M. Shimada, Y. Maehara, K. Sugimachi, Y. Yoshikai, and K. Nomoto. 2004. The critical role of Fas-Fas ligand interaction in donor-specific transfusion-induced tolerance to H-Y antigen. Transplantation 78: 799-806. (Pubitemid 39298521)
47. Alderson, M. R., R. J. Armitage, E. Maraskovsky, T. W. Tough, E. Roux, K. Schooley, F. Ramsdell, and D. H. Lynch. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178: 2231-2235.
48. Peter, M. E., R. C. Budd, J. Desbarats, S. M. Hedrick, A. O. Hueber, M. K. Newell, L. B. Owen, R. M. Pope, J. Tschopp, H. Wajant, et al. 2007. The CD95 receptor: apoptosis revisited. Cell 129: 447-450.
49. + regulatory T cells are highly susceptible to CD95 ligandbut not to TCR-mediated cell death. J. Immunol. 175: 32-36.
50. + TR cells. Int. Immunol. 18: 1265-1277.
51. Franke, D. D., E. S. Yolcu, P. Alard, M. M. Kosiewicz, and H. Shirwan. 2007. A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Mol. Immunol. 44: 2884-2892.
52. Banz, A., C. Pontoux, and M. Papiernik. 2002. Modulation of Fas-dependent apoptosis: a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J. Immunol. 169: 750-757. (Pubitemid 34753430)
53. Chen, W., M. E. Frank, W. Jin, and S. M. Wahl. 2001. TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14: 715-725. (Pubitemid 32592419)
54. Kleinclauss, F., S. Perruche, E. Masson, B. M. de Carvalho, S. Biichle, J. P. Remy-Martin, C. Ferrand, M. Martin, H. Bittard, J. M. Chalopin, et al. 2006. Intravenous apoptotic spleen cell infusion induces a TGF-β-dependent regulatory T-cell expansion. Cell Death Differ. 13: 41-52.
55. Siemionow, M., and G. Agaoglu. 2005. Role of blood transfusion in transplantation: a review. J. Reconstr. Microsurg. 21: 555-563. (Pubitemid 41739393)
56. Fudaba, Y., T. R. Spitzer, J. Shaffer, T. Kawai, T. Fehr, F. Delmonico, F. Preffer, N. Tolkoff-Rubin, B. R. Dey, S. L. Saidman, et al. 2006. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant. 6: 2121-2133. (Pubitemid 44199546)